BR112019024744A2 - Partícula e composição farmacêutica compreendendo um composto de camptotecina insolúvel com estrutura núcleo-casca dupla e método para produção da mesma - Google Patents
Partícula e composição farmacêutica compreendendo um composto de camptotecina insolúvel com estrutura núcleo-casca dupla e método para produção da mesma Download PDFInfo
- Publication number
- BR112019024744A2 BR112019024744A2 BR112019024744-0A BR112019024744A BR112019024744A2 BR 112019024744 A2 BR112019024744 A2 BR 112019024744A2 BR 112019024744 A BR112019024744 A BR 112019024744A BR 112019024744 A2 BR112019024744 A2 BR 112019024744A2
- Authority
- BR
- Brazil
- Prior art keywords
- particles
- compound
- present
- pharmaceutical composition
- double
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000011258 core-shell material Substances 0.000 abstract 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 2
- 229940127093 camptothecin Drugs 0.000 abstract 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 2
- 238000012377 drug delivery Methods 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- -1 camptothecin compound Chemical class 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000002356 single layer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção refere-se a um sistema de liberação de fármacos tendo uma estrutura do tipo núcleo-casca (core-shell) dupla e, especificamente, a um sistema duplo de liberação de nanofármacos tendo um núcleo-casca interno, contendo um composto de camptotecina fracamente solúvel e um composto de camptotecina solúvel em água no interior, e uma casca de polímero anfifílico, e a um método para produção do mesmo. as partículas com estrutura dupla núcleo-casca, produzidas pela presente invenção formam partículas muito estáveis e mostram distribuição monomodal de partículas antes e depois de secagem por congelamento. as partículas da presente invenção mostram resultados excelentes quando comparadas às micelas monocamadas existentes não fazem uso de um tensoativo causador de hipersensibilidade, portanto, o uso das partículas da presente invenção pode fornecer uma composição farmacêutica uma plataforma de sistema de liberação de fármacos, as quais são seguras para o corpo humano.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0079354 | 2017-06-22 | ||
| KR20170079354 | 2017-06-22 | ||
| PCT/KR2018/007114 WO2018236190A1 (en) | 2017-06-22 | 2018-06-22 | PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND HAVING A DOUBLE HEART-SHELL STRUCTURE AND METHOD FOR THE PRODUCTION THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019024744A2 true BR112019024744A2 (pt) | 2020-06-16 |
Family
ID=64691301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019024744-0A BR112019024744A2 (pt) | 2017-06-22 | 2018-06-22 | Partícula e composição farmacêutica compreendendo um composto de camptotecina insolúvel com estrutura núcleo-casca dupla e método para produção da mesma |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10980796B2 (pt) |
| EP (1) | EP3641730B1 (pt) |
| JP (1) | JP7027666B2 (pt) |
| KR (1) | KR102094543B1 (pt) |
| CN (1) | CN110769813A (pt) |
| AU (1) | AU2018289188B2 (pt) |
| BR (1) | BR112019024744A2 (pt) |
| CA (1) | CA3064564C (pt) |
| DK (1) | DK3641730T3 (pt) |
| ES (1) | ES2865055T3 (pt) |
| HR (1) | HRP20210767T1 (pt) |
| HU (1) | HUE053929T2 (pt) |
| IL (1) | IL270818A (pt) |
| NZ (1) | NZ759175A (pt) |
| PL (1) | PL3641730T3 (pt) |
| PT (1) | PT3641730T (pt) |
| RU (1) | RU2745070C1 (pt) |
| SI (1) | SI3641730T1 (pt) |
| WO (1) | WO2018236190A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2865055T3 (es) * | 2017-06-22 | 2021-10-14 | Snbioscience Inc | Partícula y composición farmacéutica que comprenden un compuesto de camptotecina insoluble con estructura de núcleo-cubierta doble y método para fabricar las mismas |
| EP3984630A1 (en) * | 2020-10-13 | 2022-04-20 | Paris Sciences et Lettres | Freeze-dried microbubbles, their use, and method for producing the same |
| WO2022114736A1 (ko) * | 2020-11-27 | 2022-06-02 | 주식회사 에스엔바이오사이언스 | 난용성 캄토테신 화합물을 포함하는 나노 입자를 포함하는 암 치료용 약제학적 조성물 및 이의 병용요법 |
| CN114605600B (zh) * | 2022-01-18 | 2023-01-06 | 华南理工大学 | 一种酯酶响应的两亲性线性聚合物及其制备方法与应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100289074B1 (ko) * | 1998-02-04 | 2001-07-12 | 김윤 | 난용성약물함유시스템 |
| US6407117B1 (en) * | 1998-06-18 | 2002-06-18 | The George Washington University | Method of administering camptothecin compounds for the treatment of cancer with reduced side effects |
| US7217770B2 (en) * | 2000-05-17 | 2007-05-15 | Samyang Corporation | Stable polymeric micelle-type drug composition and method for the preparation thereof |
| KR100773078B1 (ko) * | 2001-06-21 | 2007-11-02 | 주식회사 삼양사 | 결정성이 높은 난용성 약물을 함유하는 고분자 미셀형약물 조성물 |
| WO2005053612A2 (en) | 2003-11-26 | 2005-06-16 | Shire Laboratories, Inc. | Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
| MX2007005293A (es) | 2004-11-05 | 2007-07-19 | Samyang Corp | Formulacion farmaceutica para incrementar la solubilidad de compuestos de 10-hidroxicamptotecina en solventes polares no acuosos. |
| US20140314864A1 (en) * | 2006-03-31 | 2014-10-23 | Massachusetts Institute Of Technology | System for Targeted Delivery of Therapeutic Agents |
| PL2644192T3 (pl) * | 2007-09-28 | 2017-09-29 | Pfizer Inc. | Ukierunkowanie na komórki nowotworowe z zastosowaniem nanocząstek |
| CN101199857B (zh) * | 2007-12-12 | 2011-04-13 | 中国药科大学 | mPEG-PLA-喜树碱类药物的结合物 |
| EA021422B1 (ru) * | 2008-06-16 | 2015-06-30 | Бинд Терапьютикс, Инк. | Полимерные наночастицы, содержащие терапевтическое средство, и способ их получения |
| ES2776126T3 (es) * | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
| EP2201935B1 (en) | 2008-12-26 | 2020-07-08 | Samyang Biopharmaceuticals Corporation | Polymeric micelle composition containing a poorly soluble drug and preparation method of the same |
| US20100203150A1 (en) | 2009-02-06 | 2010-08-12 | National Tsing Hua University | Novel amphiphilic copolymers and fabrication method thereof |
| US8299178B2 (en) * | 2009-03-25 | 2012-10-30 | National Tsing Hua University | Stable micelles formed with diblock copolymers of critical micelle concentration copolymer and temperature-sensitive copolymer |
| CN101869712B (zh) | 2009-04-21 | 2016-01-20 | 财团法人工业技术研究院 | 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物 |
| CN101628919B (zh) * | 2009-08-20 | 2011-11-23 | 浙江大学 | 喜树碱及其衍生物的自乳化药物前体及其应用 |
| CN102933658A (zh) | 2009-12-18 | 2013-02-13 | 界面生物公司 | 从自组装涂层局部递送药物 |
| CA2830240A1 (en) | 2011-03-15 | 2012-09-20 | The University Of North Carolina At Chapell Hill | Methods of treating breast cancer with anthracycline therapy |
| CN102746314B (zh) | 2011-04-18 | 2016-07-06 | 华东师范大学 | 含有稳定7元内酯环的喜树碱类化合物、制备方法和用途 |
| US9931410B2 (en) | 2012-10-09 | 2018-04-03 | The Brigham And Women's Hospital, Inc. | Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use |
| CN102961332A (zh) * | 2012-12-05 | 2013-03-13 | 复旦大学 | 提高喜树碱类衍生物活性闭环率的液体胶束制剂及其制备方法和应用 |
| CN103638027B (zh) * | 2013-11-08 | 2016-03-09 | 浙江大学 | 利用双亲性药物包载疏水性抗肿瘤药物的方法及制剂 |
| GB201412841D0 (en) | 2014-07-18 | 2014-09-03 | Univ Liverpool | Particles |
| KR102498088B1 (ko) | 2015-12-30 | 2023-02-09 | 코웨이 주식회사 | 폐수의 재활용이 가능한 이동식 헤어 클리닝 시스템 |
| ES2865055T3 (es) | 2017-06-22 | 2021-10-14 | Snbioscience Inc | Partícula y composición farmacéutica que comprenden un compuesto de camptotecina insoluble con estructura de núcleo-cubierta doble y método para fabricar las mismas |
-
2018
- 2018-06-22 ES ES18821648T patent/ES2865055T3/es active Active
- 2018-06-22 WO PCT/KR2018/007114 patent/WO2018236190A1/en unknown
- 2018-06-22 SI SI201830281T patent/SI3641730T1/sl unknown
- 2018-06-22 US US16/015,470 patent/US10980796B2/en active Active
- 2018-06-22 PT PT188216485T patent/PT3641730T/pt unknown
- 2018-06-22 AU AU2018289188A patent/AU2018289188B2/en active Active
- 2018-06-22 HU HUE18821648A patent/HUE053929T2/hu unknown
- 2018-06-22 JP JP2020520413A patent/JP7027666B2/ja active Active
- 2018-06-22 NZ NZ759175A patent/NZ759175A/en unknown
- 2018-06-22 PL PL18821648T patent/PL3641730T3/pl unknown
- 2018-06-22 KR KR1020180072357A patent/KR102094543B1/ko active IP Right Grant
- 2018-06-22 DK DK18821648.5T patent/DK3641730T3/da active
- 2018-06-22 BR BR112019024744-0A patent/BR112019024744A2/pt active Search and Examination
- 2018-06-22 RU RU2019136373A patent/RU2745070C1/ru active
- 2018-06-22 CA CA3064564A patent/CA3064564C/en active Active
- 2018-06-22 EP EP18821648.5A patent/EP3641730B1/en active Active
- 2018-06-22 CN CN201880041446.5A patent/CN110769813A/zh active Pending
-
2019
- 2019-11-21 IL IL270818A patent/IL270818A/en unknown
-
2021
- 2021-04-16 US US17/233,091 patent/US20210228569A1/en not_active Abandoned
- 2021-04-16 US US17/233,040 patent/US11793803B2/en active Active
- 2021-04-16 US US17/233,069 patent/US11793804B2/en active Active
- 2021-04-16 US US17/233,153 patent/US20210308122A1/en not_active Abandoned
- 2021-05-13 HR HRP20210767TT patent/HRP20210767T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210236480A1 (en) | 2021-08-05 |
| PL3641730T3 (pl) | 2021-08-23 |
| EP3641730A1 (en) | 2020-04-29 |
| US11793804B2 (en) | 2023-10-24 |
| HUE053929T2 (hu) | 2021-07-28 |
| CN110769813A (zh) | 2020-02-07 |
| EP3641730B1 (en) | 2021-03-03 |
| IL270818A (en) | 2020-01-30 |
| RU2745070C1 (ru) | 2021-03-18 |
| KR102094543B1 (ko) | 2020-03-27 |
| US10980796B2 (en) | 2021-04-20 |
| DK3641730T3 (da) | 2021-05-03 |
| US20210308122A1 (en) | 2021-10-07 |
| KR20190000325A (ko) | 2019-01-02 |
| WO2018236190A1 (en) | 2018-12-27 |
| AU2018289188B2 (en) | 2020-12-24 |
| HRP20210767T1 (hr) | 2021-07-23 |
| PT3641730T (pt) | 2021-04-01 |
| SI3641730T1 (sl) | 2021-08-31 |
| US20210228568A1 (en) | 2021-07-29 |
| NZ759175A (en) | 2022-07-01 |
| JP7027666B2 (ja) | 2022-03-02 |
| CA3064564A1 (en) | 2018-12-27 |
| US11793803B2 (en) | 2023-10-24 |
| EP3641730A4 (en) | 2020-06-24 |
| ES2865055T3 (es) | 2021-10-14 |
| US20180369231A1 (en) | 2018-12-27 |
| US20210228569A1 (en) | 2021-07-29 |
| AU2018289188A1 (en) | 2019-12-05 |
| JP2020524712A (ja) | 2020-08-20 |
| CA3064564C (en) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019024744A2 (pt) | Partícula e composição farmacêutica compreendendo um composto de camptotecina insolúvel com estrutura núcleo-casca dupla e método para produção da mesma | |
| CL2018000705A1 (es) | Método de cristalización y biodisponibilidad | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
| WO2016004048A3 (en) | Targeted conjugates and particles and formulations thereof | |
| MX2020012041A (es) | Formulacion farmaceutica. | |
| SA515361055B1 (ar) | نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون | |
| MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
| MY172519A (en) | Solid polymeric controlled release nanoparticle | |
| US20170119814A1 (en) | Therapeutic nanoparticles and methods thereof | |
| BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos | |
| IN2014MN02213A (pt) | ||
| AR093012A1 (es) | Composiciones farmaceuticas en polvo, activas, con enmascaramiento del sabor y procesos para su fabricacion | |
| JP2015535243A5 (pt) | ||
| WO2019090030A8 (en) | Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations | |
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| WO2016130800A3 (en) | Pharmaceutical compositions comprising perillyl alcohol derivatives | |
| FI3229776T3 (fi) | Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt | |
| PE20171246A1 (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos | |
| CL2018003688A1 (es) | Método y equipo de preparación de una composición de micropartículas | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| JP2018503696A5 (pt) | ||
| Andretto et al. | Nanoemulsions Embedded in Alginate Beads as Bioadhesive Nanocomposites for Intestinal Delivery of the Anti-Inflammatory Drug Tofacitinib | |
| Soliman et al. | Miktoarm star micelles containing curcumin reduce cell viability of sensitized glioblastoma | |
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: SNBIOSCIENCE INC. (KR) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |